Urban Capital Network have launched a fund-of-funds to allow investors to tap into later-stage startups at a much lower barrier of entry. Images via urbancapitalnetwork.com

Early stage investing has always been a tried and true way for investors to get in on the ground floor of a tech company for a smaller financial commitment — but it's risky. Urban Capital Network has created an alternative.

UCN was founded to democratize investment opportunities and help investors of color find investment opportunities all while cutting their teeth as novice investors. Lenny Saizan, co-founder of UCN, says that its Horizon Fund II allows for UCN investors to get involved in venture-backed companies at a much lower price tag.

Saizan explains that UCN members are in that lower tier of accredited investors who don't necessarily have $250,000 or $1 million to invest in a fund — but they have $15,000 to $25,000 to invest.

"We allow more people to participate in venture funds or venture-backed opportunities," Saizan tells InnovationMap. "Instead of going into one deal at a very early stage, you’re getting in a later stage where the deal is more de-risked and you have a better chance of returns."

As members start to see returns on these premium investment opportunities, Saizan says, UCN encourages their investors to look at earlier stage within their own communities.

“We recognized that there was still an issue with minority founders getting funded as well,” Saizan says of UCN's mission as a whole. “We thought the best approach would be to create wealth and income within the communities that those founders would be reaching out to.”

Horizon Fund II will deploy capital in up to five funds — each with 15 to 30 portfolio companies. The first two investment opportunities have already been secured: Pegasus Tech Ventures's Pre-IPO Fund and Mercury Fund V, a Houston VC firm. In two years, UCN has seen five exits across its six funds. It's the group's second fund of funds — the first was an investment in Mercury Fund IV.

Eric Tait, co-founder at UCN, says they are looking for variety in the funds they invest in and are targeting top-tier, and highly rated VC firms all over the country that UCN's leadership has connections with.

“We’re relatively agnostic in terms of industry,” Tait says. “We do try to have a portfolio allocation that will create a return threshold that is varied.”

Typically, Tait explains, investing in a VC fund won't garner returns for seven to 10 years. However, UCN specifically targeted Pegasus's Pre-IPO Fund because ROI is expected between years two and four.

Tait says one of the things of focus for UCN this year is to grow the network's reach.

“A big goal for us is to tap into more institutional investors — like family offices, and things of that nature,” Tait says. “What we’ve realized is what we’ve been able to do for individual investors has been locked down, and we can do the same thing on a smaller scale for institutional dollars who are interested in these opportunities but don’t want to put in $1 million.”

Saizan says his team is also looking to give members a tech upgrade when it comes to accessing information and deals on UCN's platform. Additionally, he wants to focus on strengthening the group's network of VCs and how UCN interacts with them. He says firms reach out with interest all the time, and he wants to streamline that process using technology.

“We really want to formalize our network,” Saizan says. “We’re bringing diverse deal flow, diverse investors, diverse talent, and a diverse perspective. So, a lot of times VCs tap us when they are looking for an opportunity — or maybe they have an opportunity and want to know what we think.”

This week's Houston innovators to know includes Lenny Saizan of Urban Capital Network, Katie Eick of Rollin' Vets, and Tony Loyd of AECOM. Courtesy photos

3 Houston innovators to know this week

Who's who

Editor's note: This year has made for some pivotal moments for various Houston companies across industries. For some, the pandemic has meant reevaluating their business plans or increased a need for their product or service. For others, social unrest has called for systemic change. Technology emerges for these needs. This week's Houston innovators are addressing these needs with their innovative efforts.

Lenny Saizan, co-founder and managing partner

Lenny Saizan — along with three other Houston innovation leaders — founded Urban Capital Network to increase diversity and inclusion within the venture capital space. Photo via urbancapitalnetwork.com

While venture capital firms usually operate in a similar structure, Lenny Saizan and his co-founders wanted to set up Urban Capital Network differently in order to "democratize access to premium VC-backed investments," Saizan says. UCN invests into VCs that meet their diversity and inclusion requirements as a limited partner, but then also invests directly into startups as a sort of hybrid investor.

"We take a portion of our proceeds and invest in entrepreneurs of color, and we also donate to nonprofits that provide support resources for those entrepreneurs," Saizan says on this week's episode of the Houston Innovators Podcast. "We're completing the cycle. We find that it's easier to go to a VC and offer to give them money and also help them diversify their investor portfolio."

Saizan shares more about the group in the podcast episode and discusses what they've already accomplished in just a few months. Read more.

Katie Eick, founder of Rollin' Vets

Katie Eick always wanted to be able to offer mobile services. Photo courtesy of Rollin' Vets

Katie Eick founded her mobile vet company in 2016 after years of wanting to be able to provide the type and level of service she has now at Rollin' Vets. While convenience technologies like delivery apps buoyed her company's steady growth, the pandemic really established market need for her business model.

"We were continuously growing slowly — then COVID hit. It really cemented that … all the convenience services are in the forefront of people's minds." Eick tells InnovationMap. "COVID made it clear that this was a necessary service."

Now, she plans to adopt a franchising model and is planning an expansion into San Antonio and Dallas before going national. Read more.

Tony Loyd, vice president at AECOM

Just like Hurricane Harvey, COVID-19 is causing Houstonians to rethink how they operate — and that tech and innovation inversion is opening the door to new opportunities. Courtesy Photo

COVID-19 is affecting the evolution of technology — it's as simple as that, according to Tony Loyd. And it's not the first time — nor the last — that consumer needs affect tech innovation.

"Could COVID-19 be triggering an inversion paradigm? An inversion paradigm puts needs first rather than product first," writes Loyd in a guest column for InnovationMap. "We have experienced many historic technology inversions. Remember when our televisions were air-wave dependent and telephones were tethered to the wall? Because the need evolved for a phone that was mobile, today our TV's are wired, and our telephones are untethered." Read more.

Lenny Saizan — along with three other Houston innovation leaders — founded Urban Capital Network to increase diversity and inclusion within the venture capital space. Photo via urbancapitalnetwork.com

This investor is democratizing access to venture capital deals in Houston while promoting inclusion

HOUSTON INNOVATORS PODCAST EPISODE 47

The Urban Capital Network, which launched in Houston earlier this year, gets the best of both worlds. Not only is the group working with venture capital firms as a limited partner, but, operating as a hybrid investor, UCN also is funding startups directly — using both avenues to promote diversity and inclusion.

"We can be described as a hybrid between an angel investment group and a small VC firm," says Lenny Saizan, co-founder and managing partner of Urban Capital Network. "Our mission is to democratize access to premium VC-backed investments."

By forming relationships with VC funds — specifically ones that value UCN's diversity and inclusion platform — the group's network of investors can form syndicates, or group investments, to work with these funds on deals they otherwise couldn't afford to invest into. The VCs benefit in that they have access to new limited partners.

Saizan says UCN has raised $3 million in six months, and all that's been invested.

"We take a portion of our proceeds and invest in entrepreneurs of color, and we also donate to nonprofits that provide support resources for those entrepreneurs," Saizan says on this week's episode of the Houston Innovators Podcast. "We're completing the cycle. We find that it's easier to go to a VC and offer to give them money and also help them diversify their investor portfolio."

Saizan has three business partners, who each provides their own expertise to UCN: Heath Butler, network partner at Houston-based Mercury Fund; Felix Chevalier, founder of The Chevalier Law Firm; and Dr. Eric S. Tait president of Vernonville Asset Management.

Saizan discusses some of the challenges and opportunities the pandemic has provided UCN and where he and his co-founders are planning to take the investment group in the episode of the podcast. You can listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from eaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in the HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”